Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/8987
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTheodorus Sutanto, Samuel-
dc.contributor.authorSinto, Robert-
dc.contributor.authorPasaribu, Adeline-
dc.contributor.authorShakinah, Sharifah-
dc.date.accessioned2024-12-14T03:42:57Z-
dc.date.available2024-12-14T03:42:57Z-
dc.date.issued2022-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/8987-
dc.description.abstractCoronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, molnupiravir and nirmatrelvir/ ritonavir, that have been studied extensively in treating COVID-19 with promising results, and their availability in Indonesia. Molnupiravir and nirmatrelvir/ritonavir are two of many repurposed drugs in clinical trials, which have been reported to have a mechanism in quick clearance of SARS-CoV-2, reduction in viral load, and fast symptoms recovery time in phase 1 and 2 clinical trials. Phase 2/3 clinical study in COVID-19 patients without any indication for hospitalization showed that molnupiravir and nirmatrelvir/ritonavir significantly reduced the risk of hospitalization and death. Keywords: antiviral, COVID-19, molnupiravir, nirmatrelvir/ritonavir, SARS-CoV-2.en_US
dc.subjectantiviral, COVID-19, molnupiravir, nirmatrelvir/ritonavir, SARS-CoV-2.en_US
dc.titleMolnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19en_US
dc.typeArticleen_US
Appears in Collections:VOL 54 NO 4 2022

Files in This Item:
File Description SizeFormat 
16.crdownload387.33 kBUnknownView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.